Alembic Q1 net rises 2%

Image
BS Reporter Mumbai/ Ahmedabad
Last Updated : Jan 25 2013 | 4:04 AM IST

Vadodara based Alembic Pharmaceuticals has posted a 2.4 per cent rise in net profit for the first quarter of the fiscal ended June 30, 2012 at Rs 27.28 crore on the back of a 14 per cent rise in its domestic formulations sales and a 37 per cent growth in active pharmaceutical ingredients (API) exports . Net sales for the quarter under review stood at Rs 340.7 crore, up 5.5 per cent from Rs 322.7 crore in the year-before period.

On a consolidated basis, the company posted a 12 per cent rise in net profit to Rs 30.83 crore in Q1FY13, up from Rs 27.56 crore in the corresponding quarter in 2011-12 fiscal. Net sales was up 7 per cent to Rs 368 crore during the quarter under review against Rs 345 crore in corresponding quarter last year.

Domestic formulations sales was up 14 per cent during the quarter at Rs 197 crore against Rs 172 crore in the same period a year before. Formulation export sales were up marginally at Rs 139 crore during the quarter from Rs 137 crore in Q1FY12. For the quarter, API exports stood at Rs 83.48 crore against Rs 60.73 crore in the year-before period.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 10 2012 | 12:48 AM IST

Next Story